Pricing Log in Create free account
Saturday 17 October 2026 Export CRBU’s income statement to Excel — free account

Caribou Biosciences, Inc.

CRBU Healthcare Biotechnology

Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue fell 43.8%, EPS grew 58.6% and free cash flow fell 33.2%, each against the same quarter a year earlier.

0.47 0.00 0.00%
Market cap
$49.8M
P/E
0.0×
Fwd P/E
−1.6×
Dividend yield
—
F-score
3/9
Altman Z
−5.00
Beneish M
−3.93
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.05
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — 5 — — — — — — — —
Insider Ownership 3.39%

Capital & Financial Ratios $m

Market Cap 49.82
Revenue 10.04
Net Income (103.40)
Free Cash Flow (132.79)
Net Debt (112.31)
Current Ratio 6.49 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.55) (negative: loss-making)
P/S ratio 4.73
P/B ratio 0.48
Past 5Y EPS Growth —
This Y EPS Growth 43.90% (at or above 15%: strong)
Next Y EPS Growth (22.42%) (below 0%: weak)
Next Y revenue growth 114.71% (at or above 10%: strong)
Next 5Y EPS Growth (2.05%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −6.5×, against a ten-year median of 3.5×; over the ten years it ranged from −13.1× in 2025 to 80.1× in 2021.
P/S against its own 10 years 1.60%
10-year low 10-year high
P/B against its own 10 years 8.05%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 329 210 139 112
Receivables 2 2 2 1
Inventory — — — —
Other 1 1 1 1
339 219 145 117
2023 2024 2025 Q'26
Payables 3 2 6 3
ST’ Debt — — — —
Other — — — —
28 31 25 18

Compound Annual Growth %

10y 5y 3y
Sales — (2.03%) (6.95%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 46.86% (25.95%)

Revenue $m

Mar Jun Sep Dec Year
’26 2 1 — — —
’25 2 3 2 4 11
’24 2 3 2 2 10
’23 4 4 24 4 34
’22 3 4 3 4 14
’21 2 1 4 3 10
’20 2 8 1 — 12
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (27) (23) — — —
’25 (37) (28) (25) (21) (111)
’24 (37) (33) (33) (35) (138)
’23 (28) (15) (29) (21) (93)
’22 (22) (22) (22) (25) (91)
’21 20 (16) (15) (21) (33)
’20 (9) (16) (9) (8) (33)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (27) 63 — — —
’25 (38) 94 (148) (21) (112)
’24 (39) (35) (33) (36) (143)
’23 (30) (18) (34) (24) (105)
’22 (22) (24) (24) (27) (97)
’21 20 (17) (16) (22) (35)
’20 (9) (17) (9) (8) (34)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.26) (0.24) — — —
’25 (0.43) (0.58) (0.30) (0.28) (1.59)
’24 (0.46) (0.42) (0.38) (0.39) (1.65)
’23 (0.46) (0.48) (0.12) (0.39) (1.38)
’22 (0.32) (0.44) (0.44) (0.44) (1.64)
’21 (1.39) (1.39) (0.46) (0.31) (2.11)
’20 (0.16) (0.22) (0.93) — (4.01)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 14.17 4.89 3.44 1.50 0.66

Analyst estimates 2026–2028

Powerpack
High — — — — — 32.65 15.85 8.59 8.33 3.54
People
People Employees — — — — — 97 137 158 147 97
Revenue/emp, $m — — — 0.00 0.00 0.10 0.10 0.22 0.07 0.12
Income, $m
Income, $m Revenue — — — 6 12 10 14 34 10 11
Gross margin, % — — — 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT — — — (31) (36) (67) (99) (102) (149) (149)
EBT margin, % — — — (535.04) (292.27) (693.92) (717.28) (295.49) (1,492.04) (1,332.33)
Net income — 0 — (23) (34) (67) (99) (102) (149) (148)
Depreciation — — — 1 1 1 1 (1) (1) 3
Per share, $
Per share, $ Revenue — — — 0.69 1.45 0.30 0.23 0.47 0.11 0.12
Earnings — — — (2.80) (4.01) (2.11) (1.64) (1.38) (1.65) (1.59)
Cash flow — — — (3.82) (3.89) (1.03) (1.50) (1.26) (1.53) (1.19)
Capex — — — (0.11) (0.04) (0.07) (0.11) (0.16) (0.05) (0.01)
Free cash flow — — — (3.93) (3.92) (1.09) (1.60) (1.42) (1.58) (1.20)
Book value — — — 0.00 2.09 12.25 4.95 4.99 2.80 1.31
Shares, m — — — 8 9 32 61 74 90 93
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 13.15 13.15 49.78 29.02 11.92 14.37 13.31
P/B — — — 0.00 0.00 1.23 1.34 1.12 0.57 1.22
EV/Sales — — — 2.98 2.98 10.62 11.14 2.39 (6.60) 0.82
EV/FCF — — — (2.82) (2.82) (2.94) (1.58) (0.78) 0.46 (0.08)
Cash, $m
Cash, $m Operating cash flow — — — (32) (33) (33) (91) (93) (138) (111)
Capex — — — (1) 0 (2) (6) (12) (5) (1)
Free cash flow — — — (33) (34) (35) (97) (105) (143) (112)
Balance, $m
Balance, $m Working capital — — — 47 12 365 232 311 189 120
Total debt — — — 42 43 0 28 — — —
Net debt — — — (41) (16) (376) (248) (329) (210) (139)
Shareholders’ equity — — — — 18 388 301 368 253 122
Returns, %
Returns, % ROA — — — 0.00 (190.36) (27.98) (24.36) (25.33) (40.00) (60.62)
ROIC — — — 0.00 (1,168.00) (349.05) (124.98) (183.29) (239.87) 0.00
ROE — — — 293.36 429.55 (36.73) (28.87) (30.50) (47.99) (78.97)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Caribou Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
INKT MiNK Therapeutics, Inc. $50.7M — (loss-making) — — n/m −32.73% (below 0%: shrinking) 0.00% 0.00% Compare
LONA LeonaBio, Inc. $49.8M — (loss-making) — — n/m −142.29% (below 0%: shrinking) 0.00% 0.00% Compare
CRBU Caribou Biosciences, Inc. $49.8M — (loss-making) — (loss-making) −43.79% (below 0%: shrinking) n/m −33.16% (below 0%: shrinking) 100.00% (1,690.39%)
MREO Mereo BioPharma Group plc - Sponsored ADR $49.3M — (loss-making) — (loss-making) — n/m +21.02% (above 0%: growing) 0.00% 0.00% Compare
HYPD Hyperion DeFi, Inc. $49.0M — (loss-making) 3.6× +2,333.33% (above 0%: growing) n/m +86.82% (above 0%: growing) 100.00% 8,668.63% Compare
HOWL Werewolf Therapeutics, Inc. $48.5M — (loss-making) — (loss-making) +256.11% (above 0%: growing) n/m +146.46% (above 0%: growing) 100.00% 34.09% Compare
ELTX Elicio Therapeutics, Inc. $48.2M — (loss-making) — (loss-making) −55.27% (below 0%: shrinking) n/m +8.77% (above 0%: growing) 0.00% 0.00% Compare
ACET Adicet Bio, Inc. $48.1M — (loss-making) — (loss-making) +727.73% (above 0%: growing) n/m +24.94% (above 0%: growing) 0.00% 0.00% Compare
KLRS Kalaris Therapeutics Inc. $47.8M — (loss-making) — — n/m +11.91% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $48.7M — — +491.92% — +16.47% 0.00% 0.00%

All 614 Biotechnology stocks →

Caribou Biosciences, Inc. (CRBU) key facts

  • Strength: Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024.
  • Caribou Biosciences, Inc. (CRBU) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CRBU traded at $0.47, a market capitalization of $49.8 million.
  • Return on equity was −79.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −5.00 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Caribou Biosciences, Inc. (CRBU) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CRBU · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com